NewLink Genetics Corp (NLNK) Expected to Post Earnings of -$0.69 Per Share

Analysts forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share of ($0.69) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for NewLink Genetics’ earnings, with estimates ranging from ($0.80) to ($0.60). NewLink Genetics reported earnings of ($0.46) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The firm is expected to report its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that NewLink Genetics will report full year earnings of ($2.65) per share for the current financial year, with EPS estimates ranging from ($2.80) to ($2.55). For the next financial year, analysts forecast that the business will post earnings of ($2.40) per share, with EPS estimates ranging from ($3.02) to ($1.62). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for NewLink Genetics.

NewLink Genetics (NASDAQ:NLNK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative net margin of 229.19% and a negative return on equity of 63.39%.

Several equities research analysts have recently issued reports on the stock. Bank of America assumed coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics in a research report on Monday, September 25th. ValuEngine downgraded shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Finally, Jefferies Group lowered their price objective on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.29.

Shares of NewLink Genetics (NLNK) opened at $8.62 on Friday. NewLink Genetics has a 12 month low of $5.90 and a 12 month high of $25.17. The company has a market cap of $318.89, a P/E ratio of -3.53 and a beta of 1.10.

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC grew its position in NewLink Genetics by 241.6% in the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 13,770 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in NewLink Genetics by 22.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 100,944 shares of the biotechnology company’s stock valued at $819,000 after purchasing an additional 18,712 shares in the last quarter. Creative Planning bought a new position in NewLink Genetics in the fourth quarter valued at $152,000. GSA Capital Partners LLP grew its position in NewLink Genetics by 653.7% in the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after purchasing an additional 114,620 shares in the last quarter. Finally, Neuberger Berman Group LLC bought a new position in NewLink Genetics in the third quarter valued at $305,000. 52.63% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/21/newlink-genetics-corp-nlnk-expected-to-post-earnings-of-0-69-per-share.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply